AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-15 (Cancel).

16. (Currently Amended) A method of facilitating entry into a cell of a therapeutic agent ~~molecule into a cell~~ that functions intracellularly comprising:

i) preparing a conjugate comprising said ~~molecule~~ agent and an HIV fusion domain, and

ii) contacting said conjugate resulting from step (i) with said cell under conditions such that conjugate binds to said cell and said entry is thereby facilitated.

17. (Currently Amended) The method according to claim 16 wherein said ~~molecule~~ agent is a peptide, polypeptide or protein.

18. (Previously Presented) The method according to claim 17 wherein said fusion domain is conjugated C-terminal or N-terminal to said peptide, polypeptide or protein.

19. (Withdrawn) The method according to claim 16 wherein said molecule is a nucleic acid.

20. (Previously Presented) The method according to claim 16 wherein said cell is a mammalian cell.

21. (Cancel).

22. (Currently Amended) The method according to claim ~~21~~ 16 wherein said ~~molecule~~ agent is an HIV regulatory protein that binds viral RNA but does not promote transcription of RNA thereby preventing normal binding of HIV transcription factors.

23. (Previously Presented) The method according to claim 16 wherein said fusion domain comprises 5 to 15 amino acids.

24. (Previously Presented) The method according to claim 23 wherein said fusion domain comprises 7 to 13 amino acids.

25. (Currently Amended) The method according to claim 24 wherein said fusion domain comprises the sequence AVGIGALFLGFL (SEQ ID NO:5).

26-31 (Cancel).

32. (New) The method according to claim 25 wherein said fusion domain consists of the sequence AVGIGALFLGFL (SEQ ID NO:5).

33. (New) The method according to claim 22 wherein said fusion domain comprises the sequence AVGIGALFLGFL (SEQ ID NO:5).

34. (New) The method according to claim 33 wherein said fusion domain consists of the sequence AVGIGALFLGFL (SEQ ID NO:5).